ArticleClinical endoscopy2026
Feasibility and diagnostic performance of heparinized wetsuction and single-pass single-needle actuation endoscopic ultrasound-guided tissue acquisition for subepithelial lesions in Japan: a single-center retrospective study.
Article in Clinical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeparinized wet suction (HEP) and the single-pass single-needle actuation method (HEP1p1a) are promising for endoscopic ultrasound-guided tissue acquisition (EUS-TA) because they improve specimen quality. However, its applicability in the biopsy of subepithelial lesions (SELs) remains unexamined. Therefore, this study evaluated the clinical utility of EUS-TA using HEP1p1a in SELs.
methodsThis study analyzed data of patients who underwent EUS-TA using HEP1p1a between January 2019 and May 2025. The primary outcome was pathological differentiation. Furthermore, clinical data of EUS-TA using HEP1p1a were compared with those using HEP and other than 1p1a; subgroup analysis was performed comparing the clinical outcomes between SELs ≥20 and <20 mm.
resultsThirty-six patients underwent EUS-TA using HEP1p1a (technical success rate: 100%): 24 and 12 patients with lesions ≥20 and <20 mm, respectively. The rates of achieving pathological differentiation, immunohistochemical success, and definitive histologic diagnosis were 94.4%, 89.3%, and 86.1%, respectively; for SELs ≥20 mm, they were 100%, 94.7%, and 95.8%, respectively. Cellularity and maximum length of white sequential specimens were better in patients with lesions ≥20 mm. No adverse events were observed during or after the procedures.
conclusionsHigh diagnostic performance and specimen quality were demonstrated with EUS-TA using HEP1p1a for SELs, particularly those >20 mm. To acquire high-quality specimens while minimizing blood contamination, EUS-TA with HEP1pla for SELs might be an effective approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.